Cargando…

Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy

BACKGROUND: Clinical T4 stage (cT4) esophageal tumors are difficult to be surgically resected, and definitive radiotherapy (RT) or chemoradiotherapy (dCRT) remains the main treatment. The study aims to analyze the association between the status of lymph node (LN) metastasis and survival outcomes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Liqiong, Zhao, Zongxing, Liu, Ao, Wang, Xin, Geng, Xiaotao, Nie, Yu, Zhao, Fen, Li, Minghuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516552/
https://www.ncbi.nlm.nih.gov/pubmed/36185192
http://dx.doi.org/10.3389/fonc.2022.774816
_version_ 1784798735891431424
author Zhu, Liqiong
Zhao, Zongxing
Liu, Ao
Wang, Xin
Geng, Xiaotao
Nie, Yu
Zhao, Fen
Li, Minghuan
author_facet Zhu, Liqiong
Zhao, Zongxing
Liu, Ao
Wang, Xin
Geng, Xiaotao
Nie, Yu
Zhao, Fen
Li, Minghuan
author_sort Zhu, Liqiong
collection PubMed
description BACKGROUND: Clinical T4 stage (cT4) esophageal tumors are difficult to be surgically resected, and definitive radiotherapy (RT) or chemoradiotherapy (dCRT) remains the main treatment. The study aims to analyze the association between the status of lymph node (LN) metastasis and survival outcomes in the cT4 stage esophageal squamous cell carcinoma (ESCC) patients that underwent treatment with dCRT or RT. METHODS: This retrospective study analyzed the clinical data of 555 ESCC patients treated with dCRT or RT at the Shandong Cancer Hospital and the Liaocheng People’s Hospital from 2010 to 2017. Kaplan–Meier and Cox regression analyses was performed to determine the relationship between LN metastasis and survival outcomes of cT4 and non-cT4 ESCC patients. The chi-square test was used to evaluate the differences in the local and distal recurrence patterns in the ESCC patients belonging to various clinical T stages. RESULTS: The 3-year survival rates for patients with non-cT4 ESCC and cT4 ESCC were 47.9% and 30.8%, respectively. The overall survival (OS) and progression-free survival (PFS) rates were strongly associated with the status of LN metastasis in the entire cohort (all P < 0.001) and the non-cT4 group (all P < 0.001) but not in the cT4 group. The local recurrence rates were 60.7% for the cT4 ESCC patients and 45.1% for the non-cT4 ESCC patients (P < 0.001). Multivariate analysis showed that clinical N stage (P = 0.002), LN size (P = 0.007), and abdominal LN involvement (P = 0.011) were independent predictors of favorable OS in the non-cT4 group. However, clinical N stage (P = 0.824), LN size (P = 0.383), and abdominal LN involvement (P = 0.337) did not show any significant correlation with OS in the cT4 ESCC patients. CONCLUSIONS: Our data demonstrated that the status of LN metastasis did not correlate with OS in the cT4 ESCC patients that received dCRT or RT. Furthermore, the prevalence of local recurrence was higher in the cT4 ESCC patients.
format Online
Article
Text
id pubmed-9516552
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95165522022-09-29 Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy Zhu, Liqiong Zhao, Zongxing Liu, Ao Wang, Xin Geng, Xiaotao Nie, Yu Zhao, Fen Li, Minghuan Front Oncol Oncology BACKGROUND: Clinical T4 stage (cT4) esophageal tumors are difficult to be surgically resected, and definitive radiotherapy (RT) or chemoradiotherapy (dCRT) remains the main treatment. The study aims to analyze the association between the status of lymph node (LN) metastasis and survival outcomes in the cT4 stage esophageal squamous cell carcinoma (ESCC) patients that underwent treatment with dCRT or RT. METHODS: This retrospective study analyzed the clinical data of 555 ESCC patients treated with dCRT or RT at the Shandong Cancer Hospital and the Liaocheng People’s Hospital from 2010 to 2017. Kaplan–Meier and Cox regression analyses was performed to determine the relationship between LN metastasis and survival outcomes of cT4 and non-cT4 ESCC patients. The chi-square test was used to evaluate the differences in the local and distal recurrence patterns in the ESCC patients belonging to various clinical T stages. RESULTS: The 3-year survival rates for patients with non-cT4 ESCC and cT4 ESCC were 47.9% and 30.8%, respectively. The overall survival (OS) and progression-free survival (PFS) rates were strongly associated with the status of LN metastasis in the entire cohort (all P < 0.001) and the non-cT4 group (all P < 0.001) but not in the cT4 group. The local recurrence rates were 60.7% for the cT4 ESCC patients and 45.1% for the non-cT4 ESCC patients (P < 0.001). Multivariate analysis showed that clinical N stage (P = 0.002), LN size (P = 0.007), and abdominal LN involvement (P = 0.011) were independent predictors of favorable OS in the non-cT4 group. However, clinical N stage (P = 0.824), LN size (P = 0.383), and abdominal LN involvement (P = 0.337) did not show any significant correlation with OS in the cT4 ESCC patients. CONCLUSIONS: Our data demonstrated that the status of LN metastasis did not correlate with OS in the cT4 ESCC patients that received dCRT or RT. Furthermore, the prevalence of local recurrence was higher in the cT4 ESCC patients. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9516552/ /pubmed/36185192 http://dx.doi.org/10.3389/fonc.2022.774816 Text en Copyright © 2022 Zhu, Zhao, Liu, Wang, Geng, Nie, Zhao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Liqiong
Zhao, Zongxing
Liu, Ao
Wang, Xin
Geng, Xiaotao
Nie, Yu
Zhao, Fen
Li, Minghuan
Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title_full Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title_fullStr Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title_full_unstemmed Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title_short Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
title_sort lymph node metastasis is not associated with survival in patients with clinical stage t4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516552/
https://www.ncbi.nlm.nih.gov/pubmed/36185192
http://dx.doi.org/10.3389/fonc.2022.774816
work_keys_str_mv AT zhuliqiong lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT zhaozongxing lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT liuao lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT wangxin lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT gengxiaotao lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT nieyu lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT zhaofen lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy
AT liminghuan lymphnodemetastasisisnotassociatedwithsurvivalinpatientswithclinicalstaget4esophagealsquamouscellcarcinomaundergoingdefinitiveradiotherapyorchemoradiotherapy